Matching articles for "opioid use disorder"

Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose

   
The Medical Letter on Drugs and Therapeutics • October 16, 2023;  (Issue 1687)
The FDA has approved an intranasal formulation of the opioid antagonist nalmefene (Opvee – Indivior) for emergency treatment of known or suspected opioid overdose in persons ≥12 years old. Nalmefene,...
The FDA has approved an intranasal formulation of the opioid antagonist nalmefene (Opvee – Indivior) for emergency treatment of known or suspected opioid overdose in persons ≥12 years old. Nalmefene, which is available by prescription, is the second opioid antagonist to become available as a nasal spray for this indication; the first was naloxone, which is now available for sale over the counter (Narcan, and generic). Other nasal spray formulations of naloxone and injectable formulations of nalmefene and naloxone are available by prescription (see Table 2).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):166-7 | Show Full IntroductionHide Full Introduction

Addendum: Over-the-Counter Narcan Nasal Spray

   
The Medical Letter on Drugs and Therapeutics • October 2, 2023;  (Issue 1686)
Since the publication of our articles entitled Drugs for Opioid Use Disorder and In Brief: Over-the-Counter Narcan Nasal Spray earlier this year, Narcan (Emergent), a nasal spray that delivers 4 mg of the...
Since the publication of our articles entitled Drugs for Opioid Use Disorder and In Brief: Over-the-Counter Narcan Nasal Spray earlier this year, Narcan (Emergent), a nasal spray that delivers 4 mg of the opioid antagonist naloxone, has become available for sale over the counter (OTC). According to the manufacturer, the retail price for a box containing 2 doses is $44.99. Some insurance companies have announced plans to cover OTC purchase of the drug for their members.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):160 | Show Full IntroductionHide Full Introduction

Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)

   
The Medical Letter on Drugs and Therapeutics • September 4, 2023;  (Issue 1684)
...
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e144-5 | Show Full IntroductionHide Full Introduction

Drugs for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • September 4, 2023;  (Issue 1684)
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne...
Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 | Show Full IntroductionHide Full Introduction

Once-Weekly or Once-Monthly Subcutaneous Buprenorphine (Brixadi) for Opioid Use Disorder

   
The Medical Letter on Drugs and Therapeutics • August 21, 2023;  (Issue 1683)
The FDA has approved a subcutaneously injected, extended-release formulation of the mu-opioid receptor partial agonist and kappa-opioid receptor antagonist buprenorphine (Brixadi – Braeburn) for...
The FDA has approved a subcutaneously injected, extended-release formulation of the mu-opioid receptor partial agonist and kappa-opioid receptor antagonist buprenorphine (Brixadi – Braeburn) for once-weekly or once-monthly treatment of moderate to severe opioid use disorder. Brixadi is the second subcutaneously injected buprenorphine formulation to be approved in the US; Sublocade, which is administered once monthly, was the first. Buprenorphine is also available for treatment of opioid use disorder in sublingual formulations with and without the opioid antagonist naloxone.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):133-5 | Show Full IntroductionHide Full Introduction